Chronic myelogenous leukemia

Michael J. Mauro, Brian J. Druker

Research output: Contribution to journalReview article

75 Scopus citations

Abstract

Chronic myelogenous leukemia (CML) is a clonal hematopoietic stem cell disorder characterized by the (9:22) translocation and resultant production of the constitutively activated bcr-abl tyrosine kinase. Characterized clinically by marked myeloid proliferation, it invariably terminates in an acute leukemia. Interferon-based regimens and stem cell transplantations are the standard therapeutic options, with stem cell transplantation being the only curative therapy. As therapy for CML improves, molecular methods of monitoring response will become integrated in patient treatment. Through rational drug development, ST1571, a bcr-abl tyrosine kinase inhibitor, has emerged as targeted therapy that offers new hope for expanded treatment options for patients with CML.

Original languageEnglish (US)
Pages (from-to)3-7
Number of pages5
JournalCurrent Opinion in Oncology
Volume13
Issue number1
DOIs
StatePublished - Jan 30 2001

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Chronic myelogenous leukemia'. Together they form a unique fingerprint.

  • Cite this